Science
-
Research updates, October 29
-
Research updates, October 22
-
Clinical trials explore how Low-Dose Naltrexone could help people with Long COVID
Observational studies suggest Low-Dose Naltrexone may benefit some people with Long COVID and ME. People with these diseases have shared their experiences with LDN in online communities, reflecting the value of patient knowledge. Now, LDN is attracting growing interest from researchers. Current clinical trials include a Long COVID study in Australia, a Spanish study focused…
-
New Long COVID and complex disease center at Mount Sinai set to be a leader in research, clinical care
Last week, a new center serving people with Long COVID and related complex chronic diseases opened at Mount Sinai Health System in New York City. Led by Dr. David Putrino, the center will be a hub for diagnosing these diseases, helping patients manage their symptoms, and running clinical trials of novel treatments. The Cohen Center…
-
Research updates, October 15
-
Research updates, October 8
-
“A good step”: Long COVID advocates and researchers respond to the RECOVER-Treating Long COVID meeting
Last week, a research symposium in Bethesda, Maryland kicked off RECOVER-Treating Long COVID, a new phase of the National Institutes of Health (NIH)’s flagship research program. The meeting included three days packed with research presentations and panel discussions aiming to advance clinical trials for the disease and capture feedback from people with Long COVID, many…
-
Research updates, October 1
*Editor’s note: The Patient-Led Research Collaborative, like The Sick Times, has received support from the Balvi and Kanro funds. Our newsroom operates independently of financial supporters. *Editor’s note, October 21: The description of the nasal spray study in Advanced Materials has been updated to more accurately describe the research and provide context. Thank you to…
-
Five reasons why the NIH should retract the “effort preference” claims in their intramural ME/CFS paper
In February, the National Institutes of Health (NIH) published a controversial paper that aimed to characterize myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome (CFS). The study, published in Nature Communications, took eight years and cost $8 million. Participants flew in from all over the country and went through intense testing on NIH’s Bethesda,…
-
Research updates, September 24
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
-
Trans people with Long COVID navigate a new “dark age” in trans health
-
National COVID-19 trends, October 13
-
Research updates, October 13
-
How I built a COVID-safer school that’s become the heart of a more caring community
-
Biological pathways and mechanistic trials centered at new Long COVID conference in Amsterdam
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance